Uprifosbuvir - Merck

Drug Profile

Uprifosbuvir - Merck

Alternative Names: IDX-21437; MK 3682

Latest Information Update: 22 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Idenix Pharmaceuticals
  • Developer Merck & Co
  • Class Antivirals; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 01 Mar 2018 Merck completes a phase II trial for Hepatitis C (Combination therapy, Treatment-naive, Treatment experienced) in Spain, Poland and the UK (NCT02956629)
  • 16 Nov 2017 Merck Sharp & Dohme completes the phase II C-BREEZE 1 trial for Hepatitis C (Combination therapy, Treatment naive, Treatment experienced) in USA (PO) (NCT02759315)
  • 20 Oct 2017 Efficacy and adverse events data from the phase II C-BREEZE 1 trial in Hepatitis C infection presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top